Abd Raboh Nermine Mohamed, Hakim Sarah Adel, Abd El Atti Rasha Mohamed
Department of Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Histol Histopathol. 2021 Mar;36(3):325-337. doi: 10.14670/HH-18-295. Epub 2020 Dec 23.
Androgen receptor (AR) interact with many pathways involved in bladder cancer development and progression. FUS (fused in liposarcoma), a multifunctional protein essential for different cellular processes, has been demonstrated as a key link between androgen receptor signaling and cell-cycle progression in prostate cancer but has not been examined in urothelial carcinoma (UC) despite an intimate association between prostate and bladder carcinogenesis.
To examine the immunohistochemical expression of AR and FUS in urothelial carcinoma in relation to prognostic parameters and to extrapolate any possible link between the expression of both markers and tumor progression.
Retrospective study using immunohistochemical staining for AR and FUS on (88) cases of urothelial carcinoma.
AR shows statistically significant relations with late tumor stage, high tumor grade, and non-papillary tumor pattern. On the other hand, FUS expression correlates with early tumor stage, low tumor grade and papillary pattern. An inverse relation is found between AR and FUS expression (p=0.001). Cases with high AR IHC expression show statistically significant shorter OS, RFS and PFS compared to cases with low AR expression. Cases with high FUS IHC expression reveal statistically significant longer OS, RFS and PFS compared to cases with low FUS expression.
FUS expression is associated with favorable prognostic parameters of UC. A possible interaction is suggested between FUS and AR pathways involved in urothelial cancer progression. Manipulating FUS levels and androgen deprivation therapy can provide new promising targets for treatment trials.
雄激素受体（AR）与膀胱癌发生发展过程中涉及的许多信号通路相互作用。FUS（脂肪肉瘤融合蛋白）是一种对不同细胞过程至关重要的多功能蛋白，已被证明是前列腺癌中雄激素受体信号传导与细胞周期进程之间的关键联系，但尽管前列腺癌和膀胱癌的发生密切相关，FUS在尿路上皮癌（UC）中的作用尚未得到研究。
研究AR和FUS在尿路上皮癌中的免疫组化表达与预后参数的关系，并推断这两种标志物的表达与肿瘤进展之间的可能联系。
采用免疫组化染色法对88例尿路上皮癌病例进行AR和FUS检测的回顾性研究。
AR与肿瘤晚期、高肿瘤分级和非乳头状肿瘤模式在统计学上具有显著相关性。另一方面，FUS表达与肿瘤早期、低肿瘤分级和乳头状模式相关。AR和FUS表达之间呈负相关（p = 0.001）。与AR低表达病例相比，AR免疫组化高表达病例的总生存期（OS）、无复发生存期（RFS）和无进展生存期（PFS）在统计学上显著缩短。与FUS低表达病例相比，FUS免疫组化高表达病例的OS、RFS和PFS在统计学上显著延长。
FUS表达与UC的良好预后参数相关。提示FUS与参与尿路上皮癌进展的AR信号通路之间可能存在相互作用。调控FUS水平和雄激素剥夺治疗可为治疗试验提供新的有前景的靶点。
